Biofortuna

Biofortuna Ltd is a HLA molecular diagnostics company providing the world’s first freeze-dried PCR reaction mix including polymerase. All the user has to do is add DNA to pre-dispensed, freeze-dried PCR reactions. It represents the ultimate in user convenience and quality. The kits are stable at ambient temperature, removing pressure on fridges and freezers. The superior kit stability reduces packaging and removes any requirements for cold shipping.

Biofortuna are developing a range of unique HLA diagnostic solutions which will address the transplantation, blood grouping, disease identification and pharmacogenetic markets.

Our first product line is targeted for the SSP transplantation market. All kits are updated after every alignment release and are designed to reduce ambiguities. All kits come with free interpretation software.

With our patented freeze-dry technology and expertise in HLA we can offer a significant advantage over our competitors. Our tests are accurate, reproducible, simple, save time, cut costs, are less manually intensive, increase throughput and can be used on current platforms.

We are an ISO 9001:2008 company and manufacture to ISO 13485 standards. All products manufactured for In Vitro Diagnostic use will carry the CE mark for compliance with the EU In Vitro Diagnostic Directive (IVDD).

"The Biofortuna product range is the only HLA typing method on the market where you just add DNA and Go. The uniquely lyophilised PCR includes all buffers and taq, removing batch and pipetting variability and ultimately improving test setup time, accuracy and cost."

Dr Mike Bunce

CEO Biofortuna